23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
18:58 , Nov 3, 2017 |  BC Week In Review  |  Company News

Nicox, Re-Vana partner for sustained-release formulations for IOP

Nicox S.A. (Euronext:COX) and Re-Vana Therapeutics Ltd. (Belfast, U.K.) partnered to develop Re-Vana's EyeLief drug delivery platform for sustained release of Nicox's stand-alone nitric oxide (NO)-donors to reduce intraocular pressure (IOP). Under the non-exclusive agreement,...
20:02 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be “satisfactorily resolved.” Earlier this month, Valeant received a second...
16:08 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Valeant gets second CRL for Vyzulta

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA issued a second complete response letter for Vyzulta latanoprostene bunod to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Valeant said the CRL...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
23:40 , Jul 7, 2017 |  BioCentury  |  Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
19:19 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

FDA approves Nicox’s Zerviate for ocular itching

Nicox S.A. (Euronext:COX) said FDA approved an NDA for Zerviate cetirizine (AC-170) to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S. Last October, FDA issued a complete response...
23:05 , May 31, 2017 |  BC Extra  |  Company News

Nicox’s Zerviate wins FDA nod for ocular itching

Nicox S.A. (Euronext:COX) jumped €2.26 (21%) to €12.85 Wednesday after FDA approved an NDA for Zerviate cetirizine to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S. In October...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....